Morgan Stanley raised the firm’s price target on ResMed (RMD) to $304 from $298 and keeps an Overweight rating on the shares. Ahead of the company’s fiscal Q1 report, the analyst notes that the firm’s Q1 revenue forecast of $1.33B is 1% below the Visible Alpha consensus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed initiated with an Equal Weight at Wells Fargo
- Resmed’s Strategic Positioning and Growth Prospects: A Buy Recommendation by Laura Sutcliffe
- Resmed’s Strategic Growth and Competitive Edge Support Buy Rating with $300 Price Target
- ResMed U.S. shares initiated with a Buy at Citi
- ResMed participates in a conference call with KeyBanc